The Role of Resistance in Candida Infections: Epidemiology and Treatment

  • J. D. Sobel
  • R. A. Akins
Part of the Infectious Disease book series (ID)

During the 1980s and 1990s there was a marked increase in the population of immunocompromised and severely ill individuals at risk of developing opportunistic fungal infections (1). In particular, the increased use of immunosuppressive agents particularly in organ transplant patients, chemotherapy and life-saving medical technology resulted in this increase of both superficial and serious invasive fungal infections (2–4).


Candida Albicans Clin Infect Candida Species Antimicrob Agent Invasive Candidiasis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Edmond MB, Wallace SE, McClish DK, Pfaller MA, Jones RN, Wenzel RP. Nosocomial bloodstream infections in United States hospitals: a three-year analysis. Clin Infect Dis. 1999;29(2):239–244PubMedCrossRefGoogle Scholar
  2. 2.
    Trick WE, Fridkin SK, Edwards JR, Hajjeh RA, Gaynes RP. Secular trend of hospital-acquired candidemia among intensive care unit patients in the United States during 1989–1999. Clin Infect Dis. 2002;35(5):627–630CrossRefGoogle Scholar
  3. 3.
    Jarvis WR. Epidemiology of nosocomial fungal infections, with emphasis on Candida species. Clin Infect Dis. 1995;20(6):1526–1530PubMedGoogle Scholar
  4. 4.
    Kao AS, Brandt ME, Pruitt WR, Conn LA, Perkins BA, Stephens DS, et al. The epidemiology of candidemia in two United States cities: results of a population-based active surveillance. Clin Infect Dis. 1999;29(5):1164–1170PubMedCrossRefGoogle Scholar
  5. 5.
    Baily GG, Perry FM, Denning DW, Mandal BK. Fluconazole-resistant candidosis in an HIV cohort. AIDS. 1994;8(6):787–792PubMedCrossRefGoogle Scholar
  6. 6.
    Feigal DW, Katz MH, Greenspan D, Westenhouse J, Winkelstein W, Jr, Lang W, et al. The prevalence of oral lesions in HIV-infected homosexual and bisexual men: three San Francisco epidemiological cohorts. AIDS. 1991;5(5):519–525PubMedCrossRefGoogle Scholar
  7. 7.
    Barchiesi F, Morbiducci V, Ancarani F, Scalise G. Emergence of oropharyngeal candidiasis caused by non-albicans species of Candida in HIV-infected patients. Eur J Epidemiol. 1993;9(4):455–456PubMedCrossRefGoogle Scholar
  8. 8.
    Kontoyiannis DP, Lewis RE. Antifungal drug resistance of pathogenic fungi. Lancet. 2002;359(9312):1135–1144PubMedCrossRefGoogle Scholar
  9. 9.
    Rowen JL, Tate JM, Nordoff N, Passarell L, McGinnis MR. Candida isolates from neonates: frequency of misidentifica-tion and reduced fluconazole susceptibility. J Clin Microbiol. 1999;37(11):3735–3737PubMedGoogle Scholar
  10. 10.
    Perea S, Patterson TF. Antifungal resistance in pathogenic fungi. Clin Infect Dis. 2002;35(9):1073–1080PubMedCrossRefGoogle Scholar
  11. 11.
    Samonis G, Anaissie EJ, Rosenbaum B, Bodey GP. A model of sustained gastrointestinal colonization by Candida albicans in healthy adult mice. Infect Immun. 1990;58(6):1514–1517PubMedGoogle Scholar
  12. 12.
    Yeo E, Alvarado T, Fainstein V, Bodey GP. Prophylaxis of oropharyngeal candidiasis with clotrimazole. J Clin Oncol. 1985;3(12):1668–1671PubMedGoogle Scholar
  13. 13.
    Klein RS, Harris CA, Small CB, Moll B, Lesser M, Friedland GH. Oral candidiasis in high-risk patients as the initial manifestation of the acquired immunodeficiency syndrome. N Engl J Med. 1984;311(6):354–358PubMedGoogle Scholar
  14. 14.
    Coleman DC, Bennett DE, Sullivan DJ, Gallagher PJ, Henman MC, Shanley DB, et al. Oral Candida in HIV infection and AIDS: new perspectives/new approaches. Crit Rev Microbiol. 1993;19(2):61–82PubMedCrossRefGoogle Scholar
  15. 15.
    Hay RJ, Clayton YM. Fluconazole in the management of patients with chronic mucocutaneous candidosis. Br J Dermatol. 1988;119(5):683–684PubMedCrossRefGoogle Scholar
  16. 16.
    Horsburgh CR, Jr, Kirkpatrick CH. Long-term therapy of chronic mucocutaneous candidiasis with ketoconazole: experience with twenty-one patients. Am J Med. 1983;74(1B):23–29PubMedCrossRefGoogle Scholar
  17. 17.
    Sobel JD, Faro S, Force RW, Foxman B, Ledger WJ, Nyirjesy PR, et al. Vulvovaginal candidiasis: epidemiologic, diagnostic, and therapeutic considerations. Am J Obstet Gynecol. 1998;178(2):203–211PubMedCrossRefGoogle Scholar
  18. 18.
    Beck-Sague C, Jarvis WR. Secular trends in the epidemiology of nosocomial fungal infections in the United States, 1980–1990 National Nosocomial Infections. Surveillance System. J Infect Dis. 1993;167(5):1247–1251Google Scholar
  19. 19.
    Fridkin SK, Jarvis WR. Epidemiology of nosocomial fungal infections. Clin Microbiol Rev. 1996;9(4):499–511PubMedGoogle Scholar
  20. 20.
    Fraser VJ, Jones M, Dunkel J, Storfer S, Medoff G, Dunagan WC. Candidemia in a tertiary care hospital: epidemiology, risk factors, and predictors of mortality. Clin Infect Dis. 1992;15(3):414–421PubMedGoogle Scholar
  21. 21.
    Fisher-Hoch SP, Hutwagner L. Opportunistic candidiasis: an epidemic of the 1980s. Clin Infect Dis. 1995;21(4):897–904PubMedGoogle Scholar
  22. 22.
    Rangel-Frausto MS, Wiblin T, Blumberg HM, Saiman L, Patterson J, Rinaldi M, et al. National epidemiology of mycoses survey (NEMIS): variations in rates of bloodstream infections due to Candida species in seven surgical intensive care units and six neonatal intensive care units. Clin Infect Dis. 1999;29(2):253–258PubMedCrossRefGoogle Scholar
  23. 23.
    McNeil MM, Nash SL, Hajjeh RA, Phelan MA, Conn LA, Plikaytis BD, et al. Trends in mortality due to invasive mycotic diseases in the United States, 1980–1997. Clin Infect Dis. 2001;33(5):641–647PubMedCrossRefGoogle Scholar
  24. 24.
    Wenzel RP, Edmond MB. Severe sepsis-national estimates. Crit Care Med. 2001;29(7):1472–1474PubMedCrossRefGoogle Scholar
  25. 25.
    Blumberg HM, Jarvis WR, Soucie JM, Edwards JE, Patterson JE, Pfaller MA, et al. Risk factors for candidal bloodstream infections in surgical intensive care unit patients: the NEMIS prospective multicenter study. The National Epidemiology of Mycosis Survey. Clin Infect Dis. 2001;33(2):177–186PubMedCrossRefGoogle Scholar
  26. 26.
    Bross J, Talbot GH, Maislin G, Hurwitz S, Strom BL. Risk factors for nosocomial candidemia: a case-control study in adults without leukemia. Am J Med. 1989;87(6):614–620PubMedCrossRefGoogle Scholar
  27. 27.
    Pappas PG, Rex JH, Lee J, Hamill RJ, Larsen RA, Powderly W, et al. A prospective observational study of candidemia: epidemiology, therapy, and influences on mortality in hospitalized adult and pediatric patients. Clin Infect Dis. 2003;37(5):634–643PubMedCrossRefGoogle Scholar
  28. 28.
    Gudlaugsson O, Gillespie S, Lee K, Vande Berg J, Hu J, Messer S, et al. Attributable mortality of nosocomial candidemia, revisited. Clin Infect Dis. 2003;37(9):1172–1177PubMedCrossRefGoogle Scholar
  29. 29.
    Wey SB, Mori M, Pfaller MA, Woolson RF, Wenzel RP. Hospital-acquired candidemia. The attributable mortality and excess length of stay. Arch Intern Med. 1988;148(12):2642–2645Google Scholar
  30. 30.
    Rentz AM, Halpern MT, Bowden R. The impact of candidemia on length of hospital stay, outcome, and overall cost of illness. Clin Infect Dis. 1998;27(4):781–788PubMedCrossRefGoogle Scholar
  31. 31.
    Girmenia C, Martino P, De Bernardis F, Gentile G, Boccanera M, Monaco M, et al. Rising incidence of Candida parapsilosis fun-gemia in patients with hematologic malignancies: clinical aspects, predisposing factors, and differential pathogenicity of the causative strains. Clin Infect Dis. 1996;23(3):506–514PubMedGoogle Scholar
  32. 32.
    Gumbo T, Isada CM, Hall G, Karafa MT, Gordon SM. Candida glabrata Fungemia. Clinical features of 139 patients. Medicine (Baltimore). 1999;78(4):220–227CrossRefGoogle Scholar
  33. 33.
    Merz WG, Karp JE, Schron D, Saral R. Increased incidence of fungemia caused by Candida krusei. J Clin Microbiol. 1986;24(4):581–584PubMedGoogle Scholar
  34. 34.
    Ghannoum MA, Rice LB. Antifungal agents: mode of action, mechanisms of resistance, and correlation of these mechanisms with bacterial resistance. Clin Microbiol Rev. 1999;12(4):501–517PubMedGoogle Scholar
  35. 35.
    Masia Canuto M, Gutierrez Rodero F. Antifungal drug resistance to azoles and polyenes. Lancet Infect Dis. 2002;2(9):550–563PubMedCrossRefGoogle Scholar
  36. 36.
    Bartizal K, Gill CJ, Abruzzo GK, Flattery AM, Kong L, Scott PM, et al. In vitro preclinical evaluation studies with the echinocandin antifungal MK-0991 (L-743,872). Antimicrob Agents Chemother. 1997;41(11):2326–2332PubMedGoogle Scholar
  37. 37.
    Rex JH, Pfaller MA, Galgiani JN, Bartlett MS, Espinel-Ingroff A, Ghannoum MA, et al. Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itra-conazole, and candida infections. Subcommittee on Antifungal Susceptibility Testing of the National Committee for Clinical Laboratory Standards. Clin Infect Dis. 1997;24(2):235–247PubMedGoogle Scholar
  38. 38.
    Rex JH, Pfaller MA, Walsh TJ, Chaturvedi V, Espinel-Ingroff A, Ghannoum MA, et al. Antifungal susceptibility testing: practical aspects and current challenges. Clin Microbiol Rev. 2001;14(4):643–658PubMedCrossRefGoogle Scholar
  39. 39.
    Rex JH, Pfaller MA, Rinaldi MG, Polak A, Galgiani JN. Antifungal susceptibility testing. Clin Microbiol Rev. 1993;6(4):367–381PubMedGoogle Scholar
  40. 40.
    Rex JH, Nelson PW, Paetznick VL, Lozano-Chiu M, Espinel-Ingroff A, Anaissie EJ. Optimizing the correlation between results of testing in vitro and therapeutic outcome in vivo for fluconazole by testing critical isolates in a murine model of invasive candidia-sis. Antimicrob Agents Chemother. 1998;42(1):129–134PubMedGoogle Scholar
  41. 41.
    Espinel-Ingroff A, Warnock DW, Vazquez JA, Arthington-Skaggs BA. In vitro antifungal susceptibility methods and clinical implications of antifungal resistance. Med Mycol. 2000;38 Suppl 1:293–304PubMedGoogle Scholar
  42. 42.
    Clancy CJ, Kauffman CA, Morris A, et al. Correlation of fluco-nazole MIC and response to therapy for patients with candidemia due to C. albicans and non-C. albicans spp: results of a multicenter prospective study of candidemia. Proceedings of the 36th Annual Meeting of the Infectious Diseases Soceity of America. Denver, CO; 1998Google Scholar
  43. 43.
    National Committee for Clinical Laboratory Standards. Reference method for broth dilution antifungal susceptibility testing of yeasts: Approved Standards. National Committee for Clinical Laboratory Standards, Wayne, PA; 1997Google Scholar
  44. 44.
    Odds FC, Motyl M, Andrade R, Bille J, Canton E, Cuenca-Estrella M, et al. Interlaboratory comparison of results of susceptibility testing with caspofungin against Candida and Aspergillus species. J Clin Microbiol. 2004;42(8):3475–3482PubMedCrossRefGoogle Scholar
  45. 45.
    Sobel JD, Zervos M, Reed BD, Hooton T, Soper D, Nyirjesy P, et al. Fluconazole susceptibility of vaginal isolates obtained from women with complicated Candida vaginitis: clinical implications. Antimicrob Agents Chemother. 2003;47(1):34–38PubMedCrossRefGoogle Scholar
  46. 46.
    Moosa MY, Sobel JD, Elhalis H, Du W, Akins RA. Fungicidal activity of fluconazole against Candida albicans in a synthetic vagina-simulative medium. Antimicrob Agents Chemother. 2004;48(1):161–167PubMedCrossRefGoogle Scholar
  47. 47.
    Clancy CJ, Nguyen MH. Correlation between in vitro susceptibility determined by E test and response to therapy with amphotericin B: results from a multicenter prospective study of candidemia. Antimicrob Agents Chemother. 1999;43(5):1289–1290PubMedGoogle Scholar
  48. 48.
    Rex JH, Pappas PG, Karchmer AW, Sobel J, Edwards JE, Hadley S, et al. A randomized and blinded multicenter trial of high-dose flu-conazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in nonneutropenic subjects. Clin Infect Dis. 2003;36(10):1221–1228PubMedCrossRefGoogle Scholar
  49. 49.
    Nguyen MH, Clancy CJ, Yu VL, Yu YC, Morris AJ, Snydman DR, et al. Do in vitro susceptibility data predict the microbiologic response to amphotericin B? Results of a prospective study of patients with Candida fungemia. J Infect Dis. 1998;177(2):425–430PubMedCrossRefGoogle Scholar
  50. 50.
    Rex JH, Cooper CR, Jr, Merz WG, Galgiani JN, Anaissie EJ. Detection of amphotericin B-resistant Candida isolates in a broth-based system. Antimicrob Agents Chemother. 1995;39(4):906–909PubMedGoogle Scholar
  51. 51.
    Warnock DW, Johnson EM, Rogers TR. Multi-centre evaluation of the Etest method for antifungal drug susceptibility testing of Candida spp. and Cryptococcus neoformans. BSAC Working Party on Antifungal Chemotherapy. J Antimicrob Chemother. 1998;42(3):321–331PubMedCrossRefGoogle Scholar
  52. 52.
    Pfaller MA, Messer SA, Bolmstrom A. Evaluation of E test for determining in vitro susceptibility of yeast isolates to amphotericin B. Diagn Microbiol Infect Dis. 1998;32(3):223–227PubMedCrossRefGoogle Scholar
  53. 53.
    Arendrup M, Lundgren B, Jensen IM, Hansen BS, Frimodt-Moller N. Comparison of Etest and a tablet diffusion test with the NCCLS broth microdilution method for fluconazole and ampho-tericin B susceptibility testing of Candida isolates. J Antimicrob Chemother. 2001;47(5):521–526PubMedCrossRefGoogle Scholar
  54. 54.
    Espinel-Ingroff A, Pfaller M, Erwin ME, Jones RN. Interlaboratory evaluation of E test method for testing antifungal susceptibilities of pathogenic yeasts to five antifungal agents by using Casitone agar and solidified RPMI 1640 medium with 2% glucose. J Clin Microbiol. 1996;34(4):848–852PubMedGoogle Scholar
  55. 55.
    Peyron F, Favel A, Michel-Nguyen A, Gilly M, Regli P, Bolmstrom A. Improved detection of amphotericin B-resistant isolates of Candida lusitaniae by E test. J Clin Microbiol. 2001;39(1):339–342PubMedCrossRefGoogle Scholar
  56. 56.
    Johnson EM, Warnock DW. Azole drug resistance in yeasts. J Antimicrob Chemother. 1995;36(5):751–755PubMedCrossRefGoogle Scholar
  57. 57.
    Ostrosky-Zeichner L, Rex JH, Pappas PG, Hamill RJ, Larsen RA, Horowitz HW, et al. Antifungal susceptibility survey of 2,000 bloodstream Candida isolates in the United States. Antimicrob Agents Chemother. 2003;47(10):3149–3154PubMedCrossRefGoogle Scholar
  58. 58.
    Pfaller MA, Diekema DJ. Epidemiology of invasive candidia-sis: a persistent public health problem. Clin Microbiol Rev. 2007;20(1):133–163PubMedCrossRefGoogle Scholar
  59. 59.
    Pfaller MA, Diekema DJ. Twelve years of fluconazole in clinical practice: global trends in species distribution and fluconazole susceptibility of bloodstream isolates of Candida. Clin Microbiol Infect. 2004;10 Suppl 1:11–23PubMedCrossRefGoogle Scholar
  60. 60.
    Pfaller MA, Diekema DJ, Jones RN, Messer SA, Hollis RJ. Trends in antifungal susceptibility of Candida spp. isolated from pediatric and adult patients with bloodstream infections: SENTRY Antimicrobial Surveillance Program, 1997 to 2000. J Clin Microbiol. 2002;40(3):852–856PubMedCrossRefGoogle Scholar
  61. 61.
    Antoniadou A, Torres HA, Lewis RE, Thornby J, Bodey GP, Tarrand JP, et al. Candidemia in a tertiary care cancer center: in vitro susceptibility and its association with outcome of initial anti-fungal therapy. Medicine (Baltimore). 2003;82(5):309–321CrossRefGoogle Scholar
  62. 62.
    Xu J, Ramos AR, Vilgalys R, Mitchell TG. Clonal and spontaneous origins of fluconazole resistance in Candida albicans. J Clin Microbiol. 2000;38(3):1214–1220PubMedGoogle Scholar
  63. 63.
    Xiao L, Madison V, Chau AS, Loebenberg D, Palermo RE, McNicholas PM. Three-dimensional models of wild-type and mutated forms of cytochrome P450 14alpha-sterol demethyl-ases from Aspergillus fumigatus and Candida albicans provide insights into posaconazole binding. Antimicrob Agents Chemother. 2004;48(2):568–574PubMedCrossRefGoogle Scholar
  64. 64.
    Hoban DJ, Zhanel GG, Karlowsky JA. In vitro susceptibilities of Candida and Cryptococcus neoformans isolates from blood cultures of neutropenic patients. Antimicrob Agents Chemother. 1999;43(6):1463–1464PubMedGoogle Scholar
  65. 65.
    Hazen KC, Baron EJ, Colombo AL, Girmenia C, Sanchez-Sousa A, del Palacio A, et al. Comparison of the susceptibilities of Candida spp. to fluconazole and voriconazole in a 4-year global evaluation using disk diffusion. J Clin Microbiol. 2003;41(12):5623–5632PubMedCrossRefGoogle Scholar
  66. 66.
    Bodey GP, Mardani M, Hanna HA, Boktour M, Abbas J, Girgawy E, et al. The epidemiology of Candida glabrata and Candida albicans fungemia in immunocompromised patients with cancer. Am J Med. 2002;112(5):380–385PubMedCrossRefGoogle Scholar
  67. 67.
    Fidel PL, Jr, Vazquez JA, Sobel JD. Candida glabrata: review of epidemiology, pathogenesis, and clinical disease with comparison to C. albicans. Clin Microbiol Rev. 1999;12(1):80–96PubMedGoogle Scholar
  68. 68.
    Safdar A, Chaturvedi V, Koll BS, Larone DH, Perlin DS, Armstrong D. Prospective, multicenter surveillance study of Candida glabrata: fluconazole and itraconazole susceptibility profiles in bloodstream, invasive, and colonizing strains and differences between isolates from three urban teaching hospitals in New York City (Candida Susceptibility Trends Study, 1998 to 1999). Antimicrob Agents Chemother. 2002;46(10):3268–3272PubMedCrossRefGoogle Scholar
  69. 69.
    Ghannoum MA, Okogbule-Wonodi I, Bhat N, Sanati H. Antifungal activity of voriconazole (UK-109,496), fluconazole and amphoter-icin B against hematogenous Candida krusei infection in neutro-penic guinea pig model. J Chemother. 1999;11(1):34–39PubMedGoogle Scholar
  70. 70.
    Imhof A, Balajee SA, Fredricks DN, Englund JA, Marr KA. Breakthrough fungal infections in stem cell transplant recipients receiving voriconazole. Clin Infect Dis. 2004;39(5):743–746PubMedCrossRefGoogle Scholar
  71. 71.
    Stiller RL, Bennett JE, Scholer HJ, Wall M, Polak A, Stevens DA. Susceptibility to 5-fluorocytosine and prevalence of serotype in 402 Candida albicans isolates from the United States. Antimicrob Agents Chemother. 1982;22(3):482–487PubMedGoogle Scholar
  72. 72.
    Ellis D. Amphotericin B: spectrum and resistance. J Antimicrob Chemother. 2002;49 Suppl 1:7–10PubMedCrossRefGoogle Scholar
  73. 73.
    Powderly WG, Kobayashi GS, Herzig GP, Medoff G. Amphotericin B-resistant yeast infection in severely immunocompromised patients. Am J Med. 1988;84(5):826–832PubMedCrossRefGoogle Scholar
  74. 74.
    Nolte FS, Parkinson T, Falconer DJ, Dix S, Williams J, Gilmore C, et al. Isolation and characterization of fluconazole- and amphoter-icin B-resistant Candida albicans from blood of two patients with leukemia. Antimicrob Agents Chemother. 1997;41(1):196–199PubMedGoogle Scholar
  75. 75.
    Merz WG, Sandford GR. Isolation and characterization of a polyene-resistant variant of Candida tropicalis. J Clin Microbiol. 1979;9(6):677–680PubMedGoogle Scholar
  76. 76.
    Rex JH, Pfaller MA. Has antifungal susceptibility testing come of age? Clin Infect Dis. 2002;35(8):982–989PubMedCrossRefGoogle Scholar
  77. 77.
    Pappas PG, Rex JH, Sobel JD, Filler SG, Dismukes WE, Walsh TJ, et al. Guidelines for treatment of candidiasis. Clin Infect Dis. 2004;38(2):161–189PubMedCrossRefGoogle Scholar
  78. 78.
    Bhargava P. Amphotericin B-resistant Candida krusei? A comparison of standardized testing and time kill studies. 40th Interscience Confrence on Antimicrobial Agents and Chemotherapy; 2000; American Society for Microbiology, Toronto, ON, Canada; 2000Google Scholar
  79. 79.
    Sterling TR, Gasser RA, Jr, Ziegler A. Emergence of resistance to amphotericin B during therapy for Candida glabrata infection in an immunocompetent host. Clin Infect Dis. 1996;23(1):187–188PubMedGoogle Scholar
  80. 80.
    Minari A, Hachem R, Raad I. Candida lusitaniae: a cause of breakthrough fungemia in cancer patients. Clin Infect Dis. 2001;32(2):186–190PubMedCrossRefGoogle Scholar
  81. 81.
    Hawkins JL, Baddour LM. Candida lusitaniae infections in the era of fluconazole availability. Clin Infect Dis. 2003;36(2):e14–8PubMedCrossRefGoogle Scholar
  82. 82.
    Krcmery V, Jr, Oravcova E, Spanik S, Mrazova-Studena M, Trupl J, Kunova A, et al. Nosocomial breakthrough fungaemia during antifungal prophylaxis or empirical antifungal therapy in 41 cancer patients receiving antineoplastic chemotherapy: analysis of aetiology risk factors and outcome. J Antimicrob Chemother. 1998;41(3):373–380PubMedCrossRefGoogle Scholar
  83. 83.
    Conly J, Rennie R, Johnson J, Farah S, Hellman L. Disseminated candidiasis due to amphotericin B-resistant Candida albicans. J Infect Dis. 1992;165(4):761–764PubMedGoogle Scholar
  84. 84.
    Pappagianis D, Collins MS, Hector R, Remington J. Development of resistance to amphotericin B in Candida lusitaniae infecting a human. Antimicrob Agents Chemother. 1979;16(2):123–126PubMedGoogle Scholar
  85. 85.
    Guinet R, Chanas J, Goullier A, Bonnefoy G, Ambroise-Thomas P. Fatal septicemia due to amphotericin B-resistant Candida lusita-niae. J Clin Microbiol. 1983;18(2):443–444PubMedGoogle Scholar
  86. 86.
    Pfaller MA, Diekema DJ, Messer SA, Hollis RJ, Jones RN. In vitro activities of caspofungin compared with those of fluconazole and itraconazole against 3,959 clinical isolates of Candida spp., including 157 fluconazole-resistant isolates. Antimicrob Agents Chemother. 2003;47(3):1068–1071PubMedCrossRefGoogle Scholar
  87. 87.
    Barchiesi F, Spreghini E, Tomassetti S, Della Vittoria A, Arzeni D, Manso E, et al. Effects of caspofungin against Candida guillier-mondii and Candida parapsilosis. Antimicrob Agents Chemother. 2006;50(8):2719–2727PubMedCrossRefGoogle Scholar
  88. 88.
    Kartsonis N, Killar J, Mixson L, Hoe CM, Sable C, Bartizal K, et al. Caspofungin susceptibility testing of isolates from patients with esophageal candidiasis or invasive candidiasis: relationship of MIC to treatment outcome. Antimicrob Agents Chemother. 2005;49(9):3616–3623PubMedCrossRefGoogle Scholar
  89. 89.
    Park S, Kelly R, Kahn JN, Robles J, Hsu MJ, Register E, et al. Specific substitutions in the echinocandin target Fks1p account for reduced susceptibility of rare laboratory and clinical Candida sp. isolates. Antimicrob Agents Chemother. 2005;49(8):3264–3273PubMedCrossRefGoogle Scholar
  90. 90.
    Hakki M, Staab JF, Marr KA. Emergence of a Candida krusei isolate with reduced susceptibility to caspofungin during therapy. Antimicrob Agents Chemother. 2006;50(7):2522–2524PubMedCrossRefGoogle Scholar
  91. 91.
    Cheung C, Guo Y, Gialanella P, Feldmesser M. Development of candidemia on caspofungin therapy: a case report. Infection. 2006;34(6):345–348PubMedCrossRefGoogle Scholar
  92. 92.
    Hernandez S, Lopez-Ribot JL, Najvar LK, McCarthy DI, Bocanegra R, Graybill JR. Caspofungin resistance in Candida albicans: correlating clinical outcome with laboratory susceptibility testing of three isogenic isolates serially obtained from a patient with progressive Candida esophagitis. Antimicrob Agents Chemother. 2004;48(4):1382–1383PubMedCrossRefGoogle Scholar
  93. 93.
    Laverdiere M, Lalonde RG, Baril JG, Sheppard DC, Park S, Perlin DS. Progressive loss of echinocandin activity following prolonged use for treatment of Candida albicans oesophagitis. J Antimicrob Chemother. 2006;57(4):705–708PubMedCrossRefGoogle Scholar
  94. 94.
    Moudgal V, Little T, Boikov D, Vazquez JA. Multiechinocandin-and multiazole-resistant Candida parapsilosis isolates serially obtained during therapy for prosthetic valve endocarditis. Antimicrob Agents Chemother. 2005;49(2):767–769PubMedCrossRefGoogle Scholar
  95. 95.
    Wingard JR, Merz WG, Rinaldi MG, Johnson TR, Karp JE, Saral R. Increase in Candida krusei infection among patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole. N Engl J Med. 1991;325(18):1274–1277PubMedCrossRefGoogle Scholar
  96. 96.
    Wingard JR, Merz WG, Rinaldi MG, Miller CB, Karp JE, Saral R. Association of Torulopsis glabrata infections with fluconazole prophylaxis in neutropenic bone marrow transplant patients. Antimicrob Agents Chemother. 1993;37(9):1847–1849PubMedGoogle Scholar
  97. 97.
    Price MF, LaRocco MT, Gentry LO. Fluconazole susceptibilities of Candida species and distribution of species recovered from blood cultures over a 5-year period. Antimicrob Agents Chemother. 1994;38(6):1422–1424PubMedGoogle Scholar
  98. 98.
    Marr KA, White TC, van Burik JA, Bowden RA. Development of fluconazole resistance in Candida albicans causing disseminated infection in a patient undergoing marrow transplantation. Clin Infect Dis. 1997;25(4):908–910PubMedCrossRefGoogle Scholar
  99. 99.
    Gleason TG, May AK, Caparelli D, Farr BM, Sawyer RG. Emerging evidence of selection of fluconazole-tolerant fungi in surgical intensive care units. Arch Surg. 1997;132(11):1197– 1201; discussion 202PubMedGoogle Scholar
  100. 100.
    Law D, Moore CB, Denning DW. Amphotericin B resistance testing of Candida spp.: a comparison of methods. J Antimicrob Chemother. 1997;40(1):109–112PubMedCrossRefGoogle Scholar
  101. 101.
    Maenza JR, Keruly JC, Moore RD, Chaisson RE, Merz WG, Gallant JE. Risk factors for fluconazole-resistant candidiasis in human immunodeficiency virus-infected patients. J Infect Dis. 1996;173(1):219–225PubMedGoogle Scholar
  102. 102.
    Fichtenbaum CJ, Powderly WG. Refractory mucosal candidiasis in patients with human immunodeficiency virus infection. Clin Infect Dis. 1998;26(3):556–565PubMedCrossRefGoogle Scholar
  103. 103.
    Fichtenbaum CJ, Koletar S, Yiannoutsos C, Holland F, Pottage J, Cohn SE, et al. Refractory mucosal candidiasis in advanced human immunodeficiency virus infection. Clin Infect Dis. 2000;30(5):749–756PubMedCrossRefGoogle Scholar
  104. 104.
    Fichtenbaum CJ, Zackin R, Rajicic N, Powderly WG, Wheat LJ, Zingman BS. Amphotericin B oral suspension for flucona-zole-refractory oral candidiasis in persons with HIV infection. Adult AIDS Clinical Trials Group Study Team 295. AIDS. 2000;14(7):845–852PubMedCrossRefGoogle Scholar
  105. 105.
    Cartledge JD, Midgley J, Gazzard BG. Non-albicans oral can-didosis in HIV-positive patients. J Antimicrob Chemother. 1999;43(3):419–422PubMedCrossRefGoogle Scholar
  106. 106.
    Goldman M. Randomized study of long-term chronic sup-pressive fluconazole vs. episodic fluconazole for patients with advanced HIV infection and history of oropharyngeal candidia-sis. 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, San Diego, CA; 2002Google Scholar
  107. 107.
    Denning DW. Can we prevent azole resistance in fungi? Lancet. 1995;346(8973):454–455PubMedCrossRefGoogle Scholar
  108. 108.
    Sobel JD, Ohmit SE, Schuman P, Klein RS, Mayer K, Duerr A, et al. The evolution of Candida species and fluconazole susceptibility among oral and vaginal isolates recovered from human immunodeficiency virus (HIV)-seropositive and at-risk HIVseronegative women. J Infect Dis. 2001;183(2):286–293PubMedCrossRefGoogle Scholar
  109. 109.
    Revankar SG, Dib OP, Kirkpatrick WR, McAtee RK, Fothergill AW, Rinaldi MG, et al. Clinical evaluation and microbiology of oropharyngeal infection due to fluconazole-resistant Candida in human immunodeficiency virus-infected patients. Clin Infect Dis. 1998;26(4):960–963PubMedCrossRefGoogle Scholar
  110. 110.
    Hope W, Morton A, Eisen DP. Increase in prevalence of nosocomial non-Candida albicans candidaemia and the association of Candida krusei with fluconazole use. J Hosp Infect. 2002;50(1):56–65PubMedCrossRefGoogle Scholar
  111. 111.
    Mahayni R, Vazquez JA, Zervos MJ. Nosocomial candidia-sis: epidemiology and drug resistance. Infect Agents Dis. 1995;4(4):248–253PubMedGoogle Scholar
  112. 112.
    Goff DA, Koletar SL, Buesching WJ, Barnishan J, Fass RJ. Isolation of fluconazole-resistant Candida albicans from human immunodeficiency virus-negative patients never treated with azoles. Clin Infect Dis. 1995;20(1):77–83PubMedGoogle Scholar
  113. 113.
    Iwen PC, Kelly DM, Reed EC, Hinrichs SH. Invasive infection due to Candida krusei in immunocompromised patients not treated with fluconazole. Clin Infect Dis. 1995;20(2):342–347PubMedGoogle Scholar
  114. 114.
    Nguyen MH, Peacock JE, Jr, Morris AJ, Tanner DC, Nguyen ML, Snydman DR, et al. The changing face of candidemia: emergence of non-Candida albicans species and antifungal resistance. Am J Med. 1996;100(6):617–623PubMedCrossRefGoogle Scholar
  115. 115.
    Abi-Said D, Anaissie E, Uzun O, Raad I, Pinzcowski H, Vartivarian S. The epidemiology of hematogenous candidiasis caused by different Candida species. Clin Infect Dis. 1997;24(6):1122–1128PubMedCrossRefGoogle Scholar
  116. 116.
    Chandra J, Kuhn DM, Mukherjee PK, Hoyer LL, McCormick T, Ghannoum MA. Biofilm formation by the fungal pathogen Candida albicans: development, architecture, and drug resistance. J Bacteriol. 2001;183(18):5385–5394PubMedCrossRefGoogle Scholar
  117. 117.
    Perumal P, Mekala S, Chaffin WL. Role for cell density in anti-fungal drug resistance in Candida albicans biofilms. Antimicrob Agents Chemother. 2007;51(7):2454–2463PubMedCrossRefGoogle Scholar
  118. 118.
    Nett J, Lincoln L, Marchillo K, Massey R, Holoyda K, Hoff B, et al. Putative role of beta-1,3 glucans in Candida albicans biofilm resistance. Antimicrob Agents Chemother. 2007;51(2):510–520PubMedCrossRefGoogle Scholar
  119. 119.
    Shuford JA, Rouse MS, Piper KE, Steckelberg JM, Patel R. Evaluation of caspofungin and amphotericin B deoxycholate against Candida albicans biofilms in an experimental intra-vascular catheter infection model. J Infect Dis. 2006;194(5):710–713PubMedCrossRefGoogle Scholar
  120. 120.
    Dick JD, Merz WG, Saral R. Incidence of polyene-resistant yeasts recovered from clinical specimens. Antimicrob Agents Chemother. 1980;18(1):158–163PubMedGoogle Scholar
  121. 121.
    Fan-Havard P, Capano D, Smith SM, Mangia A, Eng RH. Development of resistance in Candida isolates from patients receiving prolonged antifungal therapy. Antimicrob Agents Chemother. 1991;35(11):2302–2305PubMedGoogle Scholar
  122. 122.
    White TC, Marr KA, Bowden RA. Clinical, cellular, and molecular factors that contribute to antifungal drug resistance. Clin Microbiol Rev. 1998;11(2):382–402PubMedGoogle Scholar
  123. 123.
    Yoon SA, Vazquez JA, Steffan PE, Sobel JD, Akins RA. High-frequency, in vitro reversible switching of Candida lusitaniae clinical isolates from amphotericin B susceptibility to resistance. Antimicrob Agents Chemother. 1999;43(4):836–845PubMedGoogle Scholar
  124. 124.
    Dube MP, Heseltine PN, Rinaldi MG, Evans S, Zawacki B. Fungemia and colonization with nystatin-resistant Candida rugosa in a burn unit. Clin Infect Dis. 1994;18(1):77–82PubMedGoogle Scholar
  125. 125.
    Blot S, Janssens R, Claeys G, Hoste E, Buyle F, De Waele JJ, et al. Effect of fluconazole consumption on long-term trends in candidal ecology. J Antimicrob Chemother. 2006;58(2):474–477PubMedCrossRefGoogle Scholar
  126. 126.
    Marchetti O, Bille J, Fluckiger U, Eggimann P, Ruef C, Garbino J, et al. Epidemiology of candidemia in Swiss tertiary care hospitals: secular trends, 1991–2000. Clin Infect Dis. 2004;38(3):311–320PubMedCrossRefGoogle Scholar
  127. 127.
    Mathema B, Cross E, Dun E, Park S, Bedell J, Slade B, et al. Prevalence of vaginal colonization by drug-resistant Candida species in college-age women with previous exposure to over-the-counter azole antifungals. Clin Infect Dis. 2001;33(5):E23–27PubMedCrossRefGoogle Scholar
  128. 128.
    Dorrell L, Edwards A. Vulvovaginitis due to fluconazole resistant Candida albicans following self treatment with non-prescribed triazoles. Sex Transm Infect. 2002;78(4):308–309PubMedCrossRefGoogle Scholar
  129. 129.
    Sobel JD, Wiesenfeld HC, Martens M, Danna P, Hooton TM, Rompalo A, et al. Maintenance fluconazole therapy for recurrent vulvovaginal candidiasis. N Engl J Med. 2004;351(9):876–883PubMedCrossRefGoogle Scholar
  130. 130.
    Schuman P, Sobel JD, Ohmit SE, Mayer KH, Carpenter CC, Rompalo A, et al. Mucosal candidal colonization and candidiasis in women with or at risk for human immunodeficiency virus infection. HIV Epidemiology Research Study (HERS) Group. Clin Infect Dis. 1998;27(5):1161–1167PubMedCrossRefGoogle Scholar
  131. 131.
    Vazquez JA, Sobel JD, Peng G, Steele-Moore L, Schuman P, Holloway W, et al. Evolution of vaginal Candida species recovered from human immunodeficiency virus-infected women receiving fluconazole prophylaxis: the emergence of Candida gla-brata? Terry Beirn Community Programs for Clinical Research in AIDS (CPCRA). Clin Infect Dis. 1999;28(5):1025–1031PubMedCrossRefGoogle Scholar
  132. 132.
    Myoken Y, Kyo T, Fujihara M, Sugata T, Mikami Y. Clinical significance of breakthrough fungemia caused by azole-resistant Candida tropicalis in patients with hematologic malignancies. Haematologica. 2004;89(3):378–380PubMedGoogle Scholar
  133. 133.
    Goldman M, Cloud GA, Smedema M, LeMonte A, Connolly P, McKinsey DS, et al. Does long-term itraconazole prophylaxis result in in vitro azole resistance in mucosal Candida albicans isolates from persons with advanced human immunodeficiency virus infection? The National Institute of Allergy and Infectious Diseases Mycoses study group. Antimicrob Agents Chemother. 2000;44(6):1585–1587PubMedCrossRefGoogle Scholar
  134. 134.
    Muller FM, Weig M, Peter J, Walsh TJ. Azole cross-resistance to ketoconazole, fluconazole, itraconazole and voriconazole in clinical Candida albicans isolates from HIV-infected children with oropharyngeal candidosis. J Antimicrob Chemother. 2000;46(2):338–340PubMedCrossRefGoogle Scholar
  135. 135.
    Cartledge JD, Midgley J, Gazzard BG. Clinically significant azole cross-resistance in Candida isolates from HIV-positive patients with oral candidosis. AIDS. 1997;11(15):1839–1844PubMedCrossRefGoogle Scholar
  136. 136.
    Cuenca-Estrella M, Lee-Yang W, Ciblak MA, Arthington-Skaggs BA, Mellado E, Warnock DW, et al. Comparative evaluation of NCCLS M27-A and EUCAST broth microdilu-tion procedures for antifungal susceptibility testing of Candida species. Antimicrob Agents Chemother. 2002;46(11):3644–3647PubMedCrossRefGoogle Scholar
  137. 137.
    Vazquez JA, Lundstrom T, Dembry L, Chandrasekar P, Boikov D, Parri MB, et al. Invasive Candida guilliermondii infection: in vitro susceptibility studies and molecular analysis. Bone Marrow Transplant. 1995;16(6):849–853PubMedGoogle Scholar
  138. 138.
    Makarova NU, Pokrowsky V V, Kravchenko AV, Serebrovskaya LV, James MJ, McNeil MM, et al. Persistence of oropharyngeal Candida albicans strains with reduced susceptibilities to flu-conazole among human immunodeficiency virus-seropositive children and adults in a long-term care facility. J Clin Microbiol. 2003;41(5):1833–1837PubMedCrossRefGoogle Scholar
  139. 139.
    Davies A, Brailsford S, Broadley K, Beighton D. Resistance amongst yeasts isolated from the oral cavities of patients with advanced cancer. Palliat Med. 2002;16(6):527–531PubMedCrossRefGoogle Scholar
  140. 140.
    Stevens DA, Stevens JA. Cross-resistance phenotypes of flu-conazole-resistant Candida species: results with 655 clinical isolates with different methods. Diagn Microbiol Infect Dis. 1996;26(3–4):145–148PubMedCrossRefGoogle Scholar
  141. 141.
    Cuenca-Estrella M, Diaz-Guerra TM, Mellado E, Monzon A, Rodriguez-Tudela JL. Comparative in vitro activity of vori-conazole and itraconazole against fluconazole-susceptible and fluconazole-resistant clinical isolates of Candida species from Spain. Eur J Clin Microbiol Infect Dis. 1999;18(6):432–435PubMedCrossRefGoogle Scholar
  142. 142.
    Cuenca-Estrella M, Mellado E, Diaz-Guerra TM, Monzon A, Rodriguez-Tudela JL. Susceptibility of fluconazole-resistant clinical isolates of Candida spp. to echinocandin LY303366, itraconazole and amphotericin B. J Antimicrob Chemother. 2000;46(3):475–477PubMedCrossRefGoogle Scholar
  143. 143.
    Bachmann SP, Patterson TF, Lopez-Ribot JL. In vitro activity of caspofungin (MK-0991) against Candida albicans clinical isolates displaying different mechanisms of azole resistance. J Clin Microbiol. 2002;40(6):2228–2230PubMedCrossRefGoogle Scholar
  144. 144.
    Pelletier R, Loranger L, Marcotte H, De Carolis E. Voriconazole and fluconazole susceptibility of Candida isolates. J Med Microbiol. 2002;51(6):479–483PubMedGoogle Scholar
  145. 145.
    Sanguinetti M, Posteraro B, Fiori B, Ranno S, Torelli R, Fadda G. Mechanisms of azole resistance in clinical isolates of Candida glabrata collected during a hospital survey of antifungal resistance. Antimicrob Agents Chemother. 2005;49(2):668–679PubMedCrossRefGoogle Scholar
  146. 146.
    Pfaller MA, Diekema DJ. Azole antifungal drug cross-resistance: mechanisms, epidemiology, and clinical significance. J Invasive Fungal Infect. 2007;1(3):74–92Google Scholar
  147. 147.
    McKinsey DS, Wheat LJ, Cloud GA, Pierce M, Black JR, Bamberger DM, et al. Itraconazole prophylaxis for fungal infections in patients with advanced human immunodeficiency virus infection: randomized, placebo-controlled, double-blind study. National Institute of Allergy and Infectious Diseases Mycoses Study Group. Clin Infect Dis. 1999;28(5):1049–1056PubMedCrossRefGoogle Scholar
  148. 148.
    Andes D, Lepak A, Nett J, Lincoln L, Marchillo K. In vivo fluconazole pharmacodynamics and resistance development in a previously susceptible Candida albicans population examined by microbiologic and transcriptional profiling. Antimicrob Agents Chemother. 2006;50(7):2384–2394PubMedCrossRefGoogle Scholar
  149. 149.
    Andes D, Forrest A, Lepak A, Nett J, Marchillo K, Lincoln L. Impact of antimicrobial dosing regimen on evolution of drug resistance in vivo: fluconazole and Candida albicans. Antimicrob Agents Chemother. 2006;50(7):2374–2383PubMedCrossRefGoogle Scholar
  150. 150.
    Kovacicova G, Krupova Y, Lovaszova M, Roidova A, Trupl J, Liskova A, et al. Antifungal susceptibility of 262 bloodstream yeast isolates from a mixed cancer and non-cancer patient population: is there a correlation between in-vitro resistance to fluconazole and the outcome of fungemia? J Infect Chemother. 2000;6(4):216–221PubMedCrossRefGoogle Scholar
  151. 151.
    Lee SC, Fung CP, Huang JS, Tsai CJ, Chen KS, Chen HY, et al. Clinical correlates of antifungal macrodilution susceptibility test results for non-AIDS patients with severe Candida infections treated with fluconazole. Antimicrob Agents Chemother. 2000;44(10):2715–2718PubMedCrossRefGoogle Scholar
  152. 152.
    Clancy CJ, Yu VL, Morris AJ, Snydman DR, Nguyen MH. Fluconazole MIC and the fluconazole dose/MIC ratio correlate with therapeutic response among patients with candidemia. Antimicrob Agents Chemother. 2005;49(8):3171–3177PubMedCrossRefGoogle Scholar
  153. 153.
    Maenza JR, Merz WG, Romagnoli MJ, Keruly JC, Moore RD, Gallant JE. Infection due to fluconazole-resistant Candida in patients with AIDS: prevalence and microbiology. Clin Infect Dis. 1997;24(1):28–34PubMedGoogle Scholar
  154. 154.
    Laguna F, Rodriguez-Tudela JL, Martinez-Suarez J V, Polo R, Valencia E, Diaz-Guerra TM, et al. Patterns of fluconazole susceptibility in isolates from human immunodeficiency virus-infected patients with oropharyngeal candidiasis due to Candida albicans. Clin Infect Dis. 1997;24(2):124–130PubMedGoogle Scholar
  155. 155.
    Quereda C, Polanco AM, Giner C, Sanchez-Sousa A, Pereira E, Navas E, et al. Correlation between in vitro resistance to fluconazole and clinical outcome of oropharyngeal candidia-sis in HIV-infected patients. Eur J Clin Microbiol Infect Dis. 1996;15(1):30–37PubMedCrossRefGoogle Scholar
  156. 156.
    Vazquez JA. Therapeutic options for the management of oropha-ryngeal and esophageal candidiasis in HIV/AIDS patients. HIV Clin Trials. 2000;1(1):47–59PubMedCrossRefGoogle Scholar
  157. 157.
    Sangeorzan JA, Bradley SF, He X, Zarins LT, Ridenour GL, Tiballi RN, et al. Epidemiology of oral candidiasis in HIV-infected patients: colonization, infection, treatment, and emergence of flu-conazole resistance. Am J Med. 1994;97(4):339–346PubMedCrossRefGoogle Scholar
  158. 158.
    Martins MD, Lozano-Chiu M, Rex JH. Declining rates of oropha-ryngeal candidiasis and carriage of Candida albicans associated with trends toward reduced rates of carriage of fluconazole-resistant C. albicans in human immunodeficiency virus-infected patients. Clin Infect Dis. 1998;27(5):1291–1294PubMedCrossRefGoogle Scholar
  159. 159.
    Zingman BS. Resolution of refractory AIDS-related mucosal candidiasis after initiation of didanosine plus saquinavir. N Engl J Med. 1996;334(25):1674–1675PubMedCrossRefGoogle Scholar
  160. 160.
    Gruber A, Lukasser-Vogl E, Borg-von Zepelin M, Dierich MP, Wurzner R. Human immunodeficiency virus type 1 gp160 and gp41 binding to Candida albicans selectively enhances candidal virulence in vitro. J Infect Dis. 1998;177(4):1057–1063PubMedGoogle Scholar
  161. 161.
    Cassone A, De Bernardis F, Torosantucci A, Tacconelli E, Tumbarello M, Cauda R. In vitro and in vivo anticandidal activity of human immunodeficiency virus protease inhibitors. J Infect Dis. 1999;180(2):448–453PubMedCrossRefGoogle Scholar
  162. 162.
    Tacconelli E, Bertagnolio S, Posteraro B, Tumbarello M, Boccia S, Fadda G, et al. Azole susceptibility patterns and genetic relationship among oral Candida strains isolated in the era of highly active antiretroviral therapy. J Acquir Immune Defic Syndr. 2002;31(1):38–44PubMedGoogle Scholar
  163. 163.
    Barchiesi F, Maracci M, Radi B, Arzeni D, Baldassarri I, Giacometti A, et al. Point prevalence, microbiology and fluco-nazole susceptibility patterns of yeast isolates colonizing the oral cavities of HIV-infected patients in the era of highly active antiretroviral therapy. J Antimicrob Chemother. 2002;50(6):999–1002PubMedCrossRefGoogle Scholar
  164. 164.
    Bagg J, Sweeney MP, Lewis MA, Jackson MS, Coleman D, Al MA, et al. High prevalence of non-albicans yeasts and detection of anti-fungal resistance in the oral flora of patients with advanced cancer. Palliat Med. 2003;17(6):477–481PubMedCrossRefGoogle Scholar
  165. 165.
    Silverman S, Jr, Luangjarmekorn L, Greenspan D. Occurrence of oral Candida in irradiated head and neck cancer patients. J Oral Med. 1984;39(4):194–196PubMedGoogle Scholar
  166. 166.
    Rautemaa R, Richardson M, Pfaller M, Koukila-Kahkola P, Perheentupa J, Saxen H. Decreased susceptibility of Candida albicans to azole antifungals: a complication of long-term treatment in autoimmune polyendocrinopathy-candidiasis- ectodermal dystrophy (APECED) patients. J Antimicrob Chemother. 2007;60(4):889–892PubMedCrossRefGoogle Scholar
  167. 167.
    Darouiche RO. Oropharyngeal and esophageal candidiasis in immunocompromised patients: treatment issues. Clin Infect Dis. 1998;26(2):259–272; quiz 73–74PubMedCrossRefGoogle Scholar
  168. 168.
    Martins MD, Rex JH. Fluconazole suspension for oropha-ryngeal candidiasis unresponsive to tablets. Ann Intern Med. 1997;126(4):332–333PubMedGoogle Scholar
  169. 169.
    Dewsnup DH, Stevens DA. Efficacy of oral amphotericin B in AIDS patients with thrush clinically resistant to fluconazole. J Med Vet Mycol. 1994;32(5):389–393PubMedCrossRefGoogle Scholar
  170. 170.
    Grim SA, Smith KM, Romanelli F, Ofotokun I. Treatment of azole-resistant oropharyngeal candidiasis with topical amphoter-icin B. Ann Pharmacother. 2002;36(9):1383–1386PubMedCrossRefGoogle Scholar
  171. 171.
    Nguyen MT, Weiss PJ, LaBarre RC, Miller LK, Oldfield EC, Wallace MR. Orally administered amphotericin B in the treatment of oral candidiasis in HIV-infected patients caused by azole-resistant Candida albicans. AIDS. 1996;10(14):1745–1747PubMedGoogle Scholar
  172. 172.
    Cartledge JD, Midgley J, Youle M, Gazzard BG. Itraconazole cyclodextrin solution — effective treatment for HIV-related candidosis unresponsive to other azole therapy. J Antimicrob Chemother. 1994;33(5):1071–1073PubMedCrossRefGoogle Scholar
  173. 173.
    Eichel M, Just-Nubling G, Helm EB, Stille W. Itraconazole suspension in the treatment of HIV-infected patients with flu-conazole-resistant oropharyngeal candidiasis and esophagitis. Mycoses. 1996;39 Suppl 1:102–106PubMedCrossRefGoogle Scholar
  174. 174.
    Ruhnke M, Schmidt-Westhausen A, Trautmann M. In vitro activities of voriconazole (UK-109,496) against fluconazole-susceptible and -resistant Candida albicans isolates from oral cavities of patients with human immunodeficiency virus infection. Antimicrob Agents Chemother. 1997;41(3):575–577PubMedGoogle Scholar
  175. 175.
    Arathoon EG, Gotuzzo E, Noriega LM, Berman RS, DiNubile MJ, Sable CA. Randomized, double-blind, multicenter study of caspofungin versus amphotericin B for treatment of oropharyn-geal and esophageal candidiases. Antimicrob Agents Chemother. 2002;46(2):451–457PubMedCrossRefGoogle Scholar
  176. 176.
    Barbaro G, Barbarini G, Calderon W, Grisorio B, Alcini P, Di Lorenzo G. Fluconazole versus itraconazole for Candida esophagitis in acquired immunodeficiency syndrome. Candida esophagitis. Gastroenterology. 1996;111(5):1169–1177PubMedCrossRefGoogle Scholar
  177. 177.
    Hegener P, Troke PF, Fatkenheuer G, Diehl V, Ruhnke M. Treatment of fluconazole-resistant candidiasis with voriconazole in patients with AIDS. AIDS. 1998;12(16):2227–2228PubMedGoogle Scholar
  178. 178.
    Villanueva A, Arathoon EG, Gotuzzo E, Berman RS, DiNubile MJ, Sable CA. A randomized double-blind study of caspofungin versus amphotericin for the treatment of candidal esophagitis. Clin Infect Dis. 2001;33(9):1529–1535PubMedCrossRefGoogle Scholar
  179. 179.
    Villanueva A, Gotuzzo E, Arathoon EG, Noriega LM, Kartsonis NA, Lupinacci RJ, et al. A randomized double-blind study of caspofungin versus fluconazole for the treatment of esophageal candidiasis. Am J Med. 2002;113(4):294–299PubMedCrossRefGoogle Scholar
  180. 180.
    Ally R, Schurmann D, Kreisel W, Carosi G, Aguirrebengoa K, Dupont B, et al. A randomized, double-blind, double-dummy, multicenter trial of voriconazole and fluconazole in the treatment of esophageal candidiasis in immunocompromised patients. Clin Infect Dis. 2001;33(9):1447–1454PubMedCrossRefGoogle Scholar
  181. 181.
    Krause DS, Simjee AE, van Rensburg C, Viljoen J, Walsh TJ, Goldstein BP, et al. A randomized, double-blind trial of ani-dulafungin versus fluconazole for the treatment of esophageal candidiasis. Clin Infect Dis. 2004;39(6):770–775PubMedCrossRefGoogle Scholar
  182. 182.
    Sobel JD, Vazquez JA. Symptomatic vulvovaginitis due to fluconazole-resistant Candida albicans in a female who was not infected with human immunodeficiency virus. Clin Infect Dis. 1996;22(4):726–727PubMedGoogle Scholar
  183. 183.
    Sobel JD, Chaim W, Nagappan V, Leaman D. Treatment of vagin-itis caused by Candida glabrata: use of topical boric acid and flucytosine. Am J Obstet Gynecol. 2003;189(5):1297–1300PubMedCrossRefGoogle Scholar
  184. 184.
    Horowitz BJ. Topical flucytosine therapy for chronic recurrent Candida tropicalis infections. J Reprod Med. 1986;31(9):821–824PubMedGoogle Scholar
  185. 185.
    White DJ, Habib AR, Vanthuyne A, Langford S, Symonds M. Combined topical flucytosine and amphotericin B for refractory vaginal Candida glabrata infections. Sex Transm Infect. 2001;77(3):212–213PubMedCrossRefGoogle Scholar
  186. 186.
    Singh S, Sobel JD, Bhargava P, Boikov D, Vazquez JA. Vaginitis due to Candida krusei: epidemiology, clinical aspects, and therapy. Clin Infect Dis. 2002;35(9):1066–1070PubMedCrossRefGoogle Scholar
  187. 187.
    Sobel JD. Pathogenesis and treatment of recurrent vulvovaginal candidiasis. Clin Infect Dis. 1992;14 Suppl 1:S148–S153PubMedGoogle Scholar
  188. 188.
    Spinillo A, Colonna L, Piazzi G, Baltaro F, Monaco A, Ferrari A. Managing recurrent vulvovaginal candidiasis. Intermittent prevention with itraconazole. J Reprod Med. 1997;42(2):83–87PubMedGoogle Scholar
  189. 189.
    Fong IW. The value of chronic suppressive therapy with itra-conazole versus clotrimazole in women with recurrent vaginal candidiasis. Genitourin Med. 1992;68(6):374–377PubMedGoogle Scholar
  190. 190.
    Guaschino S, De Seta F, Sartore A, Ricci G, De Santo D, Piccoli M, et al. Efficacy of maintenance therapy with topical boric acid in comparison with oral itraconazole in the treatment of recurrent vul-vovaginal candidiasis. Am J Obstet Gynecol. 2001;184(4):598–602PubMedCrossRefGoogle Scholar
  191. 191.
    Eggimann P, Garbino J, Pittet D. Management of Candida species infections in critically ill patients. Lancet Infect Dis. 2003;3(12):772–785PubMedCrossRefGoogle Scholar
  192. 192.
    Rex JH, Bennett JE, Sugar AM, Pappas PG, van der Horst CM, Edwards JE, et al. A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. Candidemia Study Group and the National Institute. N Engl J Med. 1994;331(20):1325–1330PubMedCrossRefGoogle Scholar
  193. 193.
    Phillips P, Shafran S, Garber G, Rotstein C, Smaill F, Fong I, et al. Multicenter randomized trial of fluconazole versus ampho-tericin B for treatment of candidemia in non-neutropenic patients. Canadian Candidemia Study Group. Eur J Clin Microbiol Infect Dis. 1997;16(5):337–345PubMedCrossRefGoogle Scholar
  194. 194.
    Mora-Duarte J, Betts R, Rotstein C, Colombo AL, Thompson-Moya L, Smietana J, et al. Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med. 2002;347(25):2020–2029PubMedCrossRefGoogle Scholar
  195. 195.
    Kulberg BJ, Sobel JD, Ruhke N, Pappas PG. A randomized, prospective, multicenter study of voriconazole versus a regimen of amphotericin B followed by fluconazole in the treatment of candidemia in non-neutropenic patients. SubmittedGoogle Scholar
  196. 196.
    Anaissie EJ, Vartivarian SE, Abi-Said D, Uzun O, Pinczowski H, Kontoyiannis DP, et al. Fluconazole versus amphotericin B in the treatment of hematogenous candidiasis: a matched cohort study. Am J Med. 1996;101(2):170–176PubMedCrossRefGoogle Scholar
  197. 197.
    Clancy CJ, Staley B, Nguyen MH. In vitro susceptibility of breakthrough Candida bloodstream isolates correlates with daily and cumulative doses of fluconazole. Antimicrob Agents Chemother. 2006;50(10):3496–3498PubMedCrossRefGoogle Scholar
  198. 198.
    Vazquez JA, Gupta S, Villanueva A. Potential utility of recom-binant human GM-CSF as adjunctive treatment of refractory oropharyngeal candidiasis in AIDS patients. Eur J Clin Microbiol Infect Dis. 1998;17(11):781–783PubMedCrossRefGoogle Scholar
  199. 199.
    Swindells S. Pilot study of adjunctive GM-CSF (yeast derived) for fluconazole-resistant oral candidiasis in HIV-infection. Infect Dis Clin Pract. 1997;6:278–279CrossRefGoogle Scholar
  200. 200.
    Poynton CH, Barnes RA, Rees J. Interferon gamma and granu-locyte-macrophage colony-stimulating factor for the treatment of hepatosplenic candidosis in patients with acute leukemia. Clin Infect Dis. 1998;26(1):239–240PubMedCrossRefGoogle Scholar
  201. 201.
    Rokusz L, Liptay L, Kadar K. Successful treatment of chronic disseminated candidiasis with fluconazole and a granulocyte-macrophage colony-stimulating factor combination. Scand J Infect Dis. 2001;33(10):784–786PubMedCrossRefGoogle Scholar
  202. 202.
    Paterson PJ, McWhinney PH, Potter M, Kibbler CC, Prentice HG. The combination of oral amphotericin B with azoles prevents the emergence of resistant Candida species in neutropenic patients. Br J Haematol. 2001;112(1):175–180PubMedCrossRefGoogle Scholar
  203. 203.
    Fowler SL, Rhoton B, Springer SC, Messer SA, Hollis RJ, Pfaller MA. Evidence for person-to-person transmission of Candida lusitaniae in a neonatal intensive-care unit. Infect Control Hosp Epidemiol. 1998;19(5):343–345PubMedCrossRefGoogle Scholar
  204. 204.
    Burnie JP, Lee W, Williams JD, Matthews RC, Odds FC. Control of an outbreak of systemic Candida albicans. Br Med J (Clin Res Ed). 1985;291(6502):1092–1093CrossRefGoogle Scholar
  205. 205.
    Lupetti A, Tavanti A, Davini P, Ghelardi E, Corsini V, Merusi I, et al. Horizontal transmission of Candida parapsilosis can-didemia in a neonatal intensive care unit. J Clin Microbiol. 2002;40(7):2363–2369PubMedCrossRefGoogle Scholar
  206. 206.
    Ables A, Blumer NA, Valainis GT. Fluconazole prophylaxis of severe Candida infection in trauma and postsurgical patients: a porspective, double blind, randomized, placebo-controlled trial. Infect Dis Clin Pract. 2000;9:169–173CrossRefGoogle Scholar
  207. 207.
    Garbino T. Fluconazole prevents severe Candida spp. infections in high risk critically ill patients. American Society of Microbiology, Washington DC; 1997Google Scholar
  208. 208.
    Pfaller MA, Diekema DJ. Role of sentinel surveillance of candi-demia: trends in species distribution and antifungal susceptibility. J Clin Microbiol. 2002;40(10):3551–3557PubMedCrossRefGoogle Scholar

Copyright information

© Humana Press, a part of Springer Science+Business Media, LLC 2009

Authors and Affiliations

  • J. D. Sobel
    • 1
  • R. A. Akins
    • 2
  1. 1.Division of Infectious DiseasesHarper University HospitalDetroitUSA
  2. 2.Biochemistry & Molecular BiologyWayne State University, School of MedicineDetroitUSA

Personalised recommendations